• Explore /
  • Poster
  • / Phase II study of olaparib (without ADT) in men with high-risk biochemically-recurrent prostate cancer following prostatectomy, with integrated biomarker analysis.

Phase II study of olaparib (without ADT) in men with high-risk biochemically-recurrent prostate cancer following prostatectomy, with integrated biomarker analysis.

Abstract Poster

Authors

null

Benjamin A. Teply

University of Nebraska Medical Center, Omaha, NE

Benjamin A. Teply , Hao Wang , Rana Sullivan , Serina King , Catherine Handy , Tamara L. Lotan , Emmanuel S. Antonarakis

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 Genitourinary Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session A: Prostate Cancer

Track

Prostate Cancer,Prostate Cancer

Sub Track

Prostate Cancer - Advanced Disease

Clinical Trial Registration Number

NCT03047135

Citation

J Clin Oncol 36, 2018 (suppl 6S; abstr TPS386)

DOI

10.1200/JCO.2018.36.6_suppl.TPS386

Abstract #

TPS386

Poster Bd #

P4

Abstract Disclosures

Similar Posters

First Author: Emmanuel S. Antonarakis

First Author: Catherine Handy Marshall

First Author: Yao Zhu

First Author: Alicia K. Morgans